Soligenix; Announcing New FDA Drug Application Submission for Cutaneous T-cell Lymphoma

(5:37)

Soligenix; Announcing Successful Protection Using a Bivalent Thermostabilized Filovirus Vaccine

(3:52)

Soligenix; Announcing Formation of Psoriasis Medical Advisory Board

(4:43)

Revolutionizing Rare Disease Treatment: Soligenix's Breakthroughs

(6:31)

Soligenix Investor Overview

(1:37)

Learn Why Soligenix Has Recieved Over $60M in NIH and Other Government Grants

(31)

SOUN SoundHound AI Stock Analysis, Cheap Competition?!

(9:6)

'No way' for Trump to significantly increase U.S. shale production: Analyst

(3:52)

E545 Hosea 6:2 - Bullish Signals Showing Up

(42:1econd)

RedChip TV Highlights Soligenix Inc. (NASDAQ: SNGX) \u0026 Sharps Technologies (NASDAQ: STSS)

(27:1econd)

The Liquidity Event

(1:34:12)

Cramer: This biotech stock could be worth over $100 billion on an FDA approval

(5:19)

These are the stocks to buy for the next 10 years

(5:32)

NVDA \

(6:58)

Verizon CEO Hans Vestberg on Q4 results: Expecting 2-3.5% growth on the bottom line

(7:32)

Lightning Round: I prefer SoFi to Nu Holdings, says Jim Cramer

(4:46)

Soligenix, Inc - Superlative Performance in Rare Diseases

(34:41)

Soligenix's Mission in Biotech: An Interview with CEO Dr. Chris Schaber

(8:25)

FDA Grants Soligenix Fast Track Designation for Dusquetide in the Treatment of Oral Lesions

(1:11)

Learn Why Soligenix has Received $60M+ in Non-Dilutive Funding From the US Government: CEO Interview

(10:1econd)

Soligenix Updates on Heat-Stable Vaccines and Oncology Advances

(6:45)

Inside Soligenix: Innovations in Rare Disease Therapies

(2:11)

RedChip Investor Group Call with Soligenix (NASDAQ: SNGX)

(40)

SOLIGENIX PODCAST VIDEO

(8:5)

Unlocking Health Innovations: Soligenix's (NASDAQ:SNGX) Breakthrough Therapies for Rare Diseases

(7:55)

Soligenix: Late-Stage Biopharma Addressing a $2 Billion Opportunity

(12:1econd)

Soligenix: A Late-Stage Biopharma Pioneer Tackling Rare Diseases with Unmet Needs

(23)

Soligenix: Developing \u0026 Commercializing Treatments for Rare Diseases with Unmet Needs

(2:6)

RedChip Investor Group Call with Soligenix (NASDAQ: SNGX)

(48:58)